Business Wire

MN-CALABRIO

5.10.2021 16:17:12 CEST | Business Wire | Press release

Share
New Calabrio Report, Launched at Customer Event, Diagnoses Why Contact Centers Struggle with High Agent Turnover in 2021

Calabrio , the customer experience intelligence company, today unveiled its latest report, detailing first-hand agent sentiment on the current state of the contact center, the impact that “The Great Resignation” has had on contact centers and the importance of employee-centric practices. The findings were announced on the first day of the annual Calabrio Customer Connect (C3) conference. This year Calabrio’s annual conference, focused on The Connected Workforce, is being held as a virtual event October 5-6, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005256/en/

As “The Great Resignation” sweeps across the global labor landscape, many businesses are left both shorthanded and questioning what they could have done to keep their workforce. The study, entitled “Health of the Contact Center 2021: Agent Wellbeing and the Great Resignation ,” surveyed U.S. and UK contact center agents to uncover transformational opportunities for the contact center from their perspective. Calabrio previously surveyed agents on the same topic in 2017. Whereas the 2017 study was completed before the accelerated shift to remote work, 65% of this study’s respondents were speaking from experience in a hybrid or remote role. This year’s findings reveal that contact centers must prioritize agent retention and engagement or face a dangerous cycle of attrition.

The report found that contact center agents suffer tremendous stress from modern workforce challenges, including rising customer expectations, growing call volume and a shaky work-life balance. According to the study, one-third of agents report feeling acutely stressed multiple times per week. This is an increase from 2017, when just 25% of agents reported that feeling.

Even more importantly, most agents also report that their companies are not doing enough to address agent stress. This agent sentiment has created a never-ending cycle of stress and disengagement, where a third of agents are considering leaving their jobs within one year, and half plan to leave within two or three years.

“Agents are a brand’s only defenders and key ambassadors during this pandemic, and they continue to face one of the most difficult customer service eras in recent memory. Staffing levels are often low while customer expectations are high. Understanding the agent experience is the first step in providing the support they need. This report illustrates that now is the time for contact centers to prioritize the creation of a targeted agent-engagement and retention plan,” said Tom Goodmanson , president and CEO at Calabrio. “As C3 begins, we are excited to share our findings and work together with industry peers and leaders to improve the agent experience, including pushing for a more connected workforce, increased agent flexibility and a greater investment in agent-empowering technologies.”

Other takeaways from the study that tie into the C3 theme of The Connected Workforce include:

  • Money Isn’t Everything : The report found that there is a disconnect between the most asked-for items from agents and their top reasons for leaving. For example, the top ask from agents is more pay, however the top reason for leaving is being unhappy in the job. More money is the number three reason for leaving.
  • Flexibility Isn’t Just About Location: While most agents report that they are now working in their preferred environment, more flexibility is still the second most common agent request.
  • Technology Investments Are Working, But We’re Not There Yet: More agents in this year’s study feel they have the correct technology to handle challenges compared to the 2017 study, but “lack of tools” and “lack of data” are still the top two reasons agents report for why they fail to solve customer issues.

For a full report of the data and findings go to “Health of the Contact Center 2021: Agent Wellbeing and the Great Resignation .”

About Calabrio Customer Connect: October 5-6, 2021

Attend Calabrio Customer Connect (C3) to learn more about the importance of employee-centric practices and to hear from contact center peers on specific ideas for retaining staff. The annual event brings together the global contact center industry for education and networking and features more than 50 breakout sessions and keynotes from industry leaders. This year, the virtual event will feature multiple tracks to accommodate different attendees, such as the Workforce Connection, Performance Connection, Complete Connection, Partner Connection and the Connected Enterprise. To register and view this year’s breakout sessions, visit: https://www.calabriocustomerconnect.com/breakout-sessions/ .

About Calabrio

Calabrio is the customer experience intelligence company that empowers organizations to enrich human interactions. The scalability of our cloud platform allows for quick deployment of remote work models—and it gives our customers precise control over both operating costs and customer satisfaction levels. Our AI-driven analytics tools make it easy for contact centers to uncover customer sentiment and share compelling insights with other parts of the organization. Customers choose Calabrio because we understand their needs and provide a best-in-class experience, from implementation to ongoing support. Find more at calabrio.com and follow @Calabrio on Twitter.

Calabrio, Calabrio ONE® and the Calabrio logo are registered trademarks or trademarks of Calabrio, Inc. All other trademarks mentioned in this document are the property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/CalabrioInc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye